Positive samples were prepared by mixing three plasma samples from cancer patients, each positive for distinct mutations: EGFR exon 19 deletion (c.2235_2249del), EGFR p.L858R (c.2573T > G), and BRAF p.V600E (c.1799T > A). Here, BRAF is linked to cancer.